NASDAQ:ALLR Allarity Therapeutics Q4 2025 Earnings Results & Report $0.84 -0.03 (-3.91%) Closing price 04:00 PM EasternExtended Trading$0.89 +0.05 (+5.35%) As of 04:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Allarity Therapeutics beat analyst earnings expectations in its Q4 2025 results, released March 30, 2026. The company reported EPS of -$0.21 versus the -$0.22 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 30, 2026TimeBefore Market Opens Allarity Therapeutics EPS ResultsActual EPS-$0.21Consensus EPS -$0.22Beat/MissBeat by +$0.01One Year Ago EPSN/AEPS Beat Rate6 of last 7 quartersAllarity Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Allarity Therapeutics Q4 2025 Earnings FAQ Did Allarity Therapeutics beat earnings estimates for Q4 2025? Allarity Therapeutics (NASDAQ:ALLR) reported earnings of -$0.21 per share for Q4 2025, beating the consensus estimate of -$0.22. The report was announced on Monday, March 30, 2026. Allarity Therapeutics Earnings HeadlinesAllarity Therapeutics Expands Phase 2 Stenoparib Ovarian Cancer Trial to Additional Patient CohortsNovember 16 at 8:11 AM | quiverquant.comQAllarity Therapeutics Expands Phase 2 Stenoparib Trial to Three Ovarian Cancer Patient CohortsNovember 16 at 7:50 AM | globenewswire.comToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.November 17 at 1:00 AM | Behind the Markets (Ad)Allarity Therapeutics (NASDAQ:ALLR) Releases Q4 2026 Earnings GuidanceNovember 15 at 10:53 AM | americanbankingnews.comAllarity Therapeutics (NASDAQ:ALLR) Announces FY 2026 Earnings GuidanceNovember 15 at 10:53 AM | americanbankingnews.comAllarity Advances Stenoparib Pipeline; Expects Q4 Earnings Of Up To $0.04 Per ShareNovember 14 at 9:30 AM | rttnews.comSee More Allarity Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Allarity Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Allarity Therapeutics and other key companies, straight to your email. Email Address About Allarity TherapeuticsAllarity Therapeutics (NASDAQ:ALLR) is a biotechnology company focused on developing precision-medicine treatments for cancer. Its approach combines oncology drug development with tools intended to help identify patients who may be more likely to respond to a particular therapy. The company’s Drug Response Predictor (DRP) technology analyzes gene-expression data to estimate how a patient’s tumor may respond to a drug. Allarity has developed the platform for use in selecting patients for clinical studies and as a potential companion diagnostic. One of Allarity’s drug candidates is stenoparib, an oral therapy that inhibits PARP and tankyrase proteins and has been studied for ovarian cancer. The company’s work centers on advancing cancer treatments alongside diagnostic tools designed to support more individualized treatment decisions.View Allarity Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its YearThe Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to WatchTyson Foods' Earnings Beat Hides a Warning for Consumer Staples Dividend InvestorsMongoDB's Biggest Advantage May Be GitLab's Biggest WeaknessMicrosoft's Outage Barely Moved Its Stock, But a Bigger Risk May Be BuildingTyson Foods' 10% Surge Puts a Breakout in Sight, But Wall Street Remains CautiousOndas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog? Upcoming Earnings Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.